The American Pediatric Society names Dr. Tara O. Henderson as the recipient of the 2026 Norman J. Siegel New Member Outstanding Science Award
Grant and Award Announcement
Updates every hour. Last Updated: 19-Nov-2025 14:11 ET (19-Nov-2025 19:11 GMT/UTC)
2025 Tata Transformation Prize Winners
Food Security Winner: Padubidri V. Shivaprasad, PhD, National Centre for Biological Sciences
Padubidri V. Shivaprasad, PhD, addresses one of India’s greatest challenges: feeding a population projected to reach 1.5 billion by 2050 amid shrinking farmland and worsening climate stress. His groundbreaking work uses epigenetic engineering and small RNA–based modifications in rice, India’s primary staple crop, to enhance stress tolerance and nutritional quality. By precisely altering the expression of key genes, Prof. Shivaprasad’s approach surpasses the limits of conventional plant breeding, which can be slow and unpredictable. His engineered rice varieties promise to reduce fertilizer and pesticide dependence, lower production costs, and improve nutrition for millions. Beyond India, this innovation offers a sustainable blueprint for staple crops worldwide in the face of global climate change.
Sustainability Winner: Balasubramanian Gopal, PhD, Indian Institute of Science
India’s growing biomanufacturing sector urgently needs cleaner, cost-effective alternatives to traditional energy-intensive chemical synthesis methods. Balasubramanian Gopal, PhD, has developed a green chemistry platform that harnesses bioengineered E. coli bacteria to produce key chemicals used in pharmaceuticals, cosmetics, and agriculture. Integrating artificial intelligence with experimental biology, his lab rapidly designs efficient enzymes and optimizes microbial strains for high yields, without antibiotics or harmful additives. This sustainable technology can replace traditional chemical manufacturing, thus reducing pollution, enhancing domestic production, and positioning India as a global leader in environmentally responsible biomanufacturing.
Healthcare Winner: Ambarish Ghosh, PhD, Indian Institute of Science Ambarish Ghosh, PhD, is pioneering a breakthrough in cancer treatment using magnetic nanorobots – tiny, helical devices that can be safely guided through the body using magnetic fields. These nanorobots are designed to navigate complex biological environments, deliver drugs directly to tumors, and distinguish cancerous tissue from healthy cells. His team is also creating real-time imaging tools to track and steer the nanorobots during treatment. This technology promises more precise, less invasive cancer therapies with fewer side effects, with the potential to revolutionize cancer care worldwide and make advanced treatments more accessible and affordable in India and other low- and middle-income countries.
CNDP enzymes—carnosinase-1 (CNDP1) and carnosinase-2 (CNDP2)—are zinc-dependent metalloproteinases central to the metabolism of carnosine and related histidine-containing dipeptides. By maintaining carnosine homeostasis, they help modulate redox balance, glucose regulation, and cellular energy metabolism. Their dysregulation has been linked to a wide range of pathological conditions—from obesity and diabetic nephropathy to liver, gastric, and renal cancers.
A promising new targeted cancer therapy is now available to certain patients with advanced pancreatic cancer – from the comfort of their home. The treatment is available through a first-of-its-kind, entirely telehealth-based targeted cancer drug therapy nationwide clinical trial led by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
A new active substance attacks a key protein in tumour cells, leading to complete degradation. In cell experiments, this caused cancer cells to lose their protection and die. The active substance was developed by researchers at the Martin Luther University Halle-Wittenberg (MLU) and the University Medical Center Mainz. Other substances usually try to inhibit the activity of the protein “checkpoint kinase-1” (CHK1). However, if the protein is completely broken down, a chain reaction is triggered which leads to other tumour proteins being destroyed. Thus, the cancer cells are further weakened. The new study was published in the journal “Angewandte Chemie”.
Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic leukemia, CLL. The findings, published in PLOS ONE, show that mutated and unmutated forms of CLL may originate from distinct stages of B cell development, offering new insight into disease mechanisms and biomarker discovery.
A collaborative research team, led by scientists at VCU Massey Comprehensive Cancer Center and Huntsman Cancer Institute at the University of Utah, has identified a targeted drug that could effectively treat an aggressive soft tissue cancer that occurs most often in pediatric and young adult patients. New findings—published in Nature Communications—suggest that blocking a specific genetic pathway could reverse a series of tumor-driving cellular interactions to restore DNA function and benefit patients with synovial sarcoma.